Overview
- The Oxfordshire facility is authorised to produce mRNA respiratory vaccines for NHS seasonal programmes and forms part of a >£1bn UK investment.
- The site can make up to 100 million doses a year with surge capacity to 250 million during a pandemic.
- About 150 highly skilled roles are created, including 80 in manufacturing and roughly 60 scientists and lab technicians, with on‑site labs supporting global clinical trials.
- Research at the centre targets applications beyond respiratory diseases, including cancer, rare conditions and immune disorders.
- The launch follows other drugmakers pausing UK projects over the VPAG pricing row, while Moderna notes vaccines are procured outside VPAG and reiterates its long‑term commitment as ministers hail gains for health security.